Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03365791 · ClinicalTrials.gov registry record · Phase 2
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03365791 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT03365791, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
Interventions
- BIOLOGICAL PDR001
- BIOLOGICAL LAG525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2020-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03365791
The ClinicalTrials.gov registry entry for NCT03365791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PDR001 is the first listed.
NCT03365791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03365791 about?
NCT03365791 is a clinical study titled "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies". The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
What is the current status of trial NCT03365791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2018-01-24. Estimated completion is 2020-09-17.
What interventions are being tested in trial NCT03365791?
The interventions under investigation include: PDR001 (BIOLOGICAL), LAG525 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03365791?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.